Mammogen Inc. CEO Elizabeth Cormier-May Wins Illustrious Award with Business Worldwide Magazine

Eric Kristiansen • Jan 23, 2022

LONDON, Jan. 19, 2022 /PRNewswire/ -- Liz Cormier-May of Mammogen was named Biotechnology CEO of the Year – USA in the 2021 Global Corporate Excellence Awards.

The awards, run by Business Worldwide Magazine, seek to identify and honor the most respected companies and C level executives in the world. The aim is to reward outstanding performance, innovation, and ethics across international business and finance communities, covering a vast range of sectors. Liz Cormier-May won the award for her visionary approach, which is changing the face of healthcare for women all over the world.



Mammogen uses a combination of data, technology, science and personal experience to challenge the status quo. Liz is an outspoken leader in her field, and her mission is to shatter complacency and radically improve the way women's diseases are detected, diagnosed and treated. 


Breast cancer affected over 2.3 million women globally in 2020, resulting in 685,000 deaths. Mammogen is at the forefront of emerging technologies that radically improve early detection rates, potentially saving millions of lives in the process. The company also empowers women in all areas of their lives, starting new conversations about the fears, anxiety, depression, marital challenges and body shame issues that come hand in hand with breast cancer. 


Liz began her career as a medicinal chemist specialising in early discovery oncology at the Novartis institute for Biomedical Research. For almost 20 years, she has been developing new markets, products and companies, with one shared goal – to introduce novel options and technologies that enhance patient experiences and save lives.


As well as leading Mammogen, Liz is also the CCO of IV Bioholdings; a bio innovation studio that conceives, creates and develops first-in-category RNA bio platforms which radically improve the detection, diagnosis and treatment of disease. To date, IV BioHoldings has created three first in class new biopsy programs, eight clinical stage diagnostics, and has discovered over two hundred novel RNA biomarkers. Together these have the potential to save over a billion lives around the world.


To find out more about Mammogen's innovative, life saving technologies, visit https://www.mammogen.bio

Further information on the individuals and companies which picked up titles in the Global Corporate Excellence Awards 2021, can be found at: https://www.bwmonline.com/2021-global-corporate-excellence-awards-winners/

About Business Worldwide Magazine

Business Worldwide Magazine is the leading source of business and dealmaker intelligence throughout the world. Our quarterly magazine and online news portal enable an established audience of corporate dealmakers to track the latest news, stories and developments affecting the international markets, corporate finance, business strategy and changes in legislation. This readership includes of CEO/CFO - Banks, Corporate Lawyers and Venture Capital/Private Equity Companies to name a few.

02 Dec, 2023
Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer
02 Dec, 2023
272 | "Changing Lives Through Early Disease Detection" with Marty Keiser from IVBH Studio
16 Nov, 2023
World's First Early Detection Blood Test to Unlock Stage I Diagnosis of Breast Cancer
Show More
02 Dec, 2023
Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer
02 Dec, 2023
272 | "Changing Lives Through Early Disease Detection" with Marty Keiser from IVBH Studio
16 Nov, 2023
World's First Early Detection Blood Test to Unlock Stage I Diagnosis of Breast Cancer
By Eric Kristiansen 04 Jun, 2023
IVBH's novel RNA approach to early detection demonstrates strong sensitivity and specificity for early lung cancer detection, in a large, predominantly early-stage, independent validation cohort
By Marty Keiser 22 Mar, 2023
A decade in the making, AI is suddenly everything, everywhere, all at once. In this article I outline three major themes emerging in the current environment. 1. Industrialization. We have officially entered the industrialization era of AI. With the most complex technical foundation already having been laid, success is no longer about the quality of your code, but rather the quality of your prompts. Any person with the right idea, the right focus, and the right prompts, can now solve any problem, in any industry, regardless of their background, socioeconomic status or geography. The floodgates for innovation have officially been opened. 2. Business disruption. Big missions no longer require big teams, big infrastructure, or big budgets. In fact, in the age of abundance, these things are detractors from the mission. Regime change is underway and small, nimble, multi-disciplinary teams who leverage big data and generalized AI tools in a highly specialized way should not be underestimated or undervalued. Size is no longer an advantage, it’s an Achilles heel. 3. People disruption. AI has reached a point where it can now scale humans. The net effect of this is a devaluing of humans without AI, and a devaluing of AI without humans. The two can no longer be treated as mutually exclusive. Humans who fully embrace AI with intention and purpose will win, and they will win big. (The humans who do this most effectively within this decade will be the winners for the next century.)
By Eric Kristiansen 17 Mar, 2023
"Marty Keiser, an accomplished entrepreneur and finance professional, shares his wealth of knowledge and experience in growing and scaling a successful business. From navigating the transition into the science industry (from the finance world), key lessons learned in building a strong and effective team, the challenges faced during growth, and the importance of preserving company culture, Marty sheds light on topics that any entrepreneur or leader can benefit from. He also offers practical insights on defining core values, using those values to guide the hiring process, and identifying the right individuals for your teams. All valuable information for those seeking to grow their own business or improve their leadership within their organization. Marty is also sharing practical resources for listeners!"
By Eric Kristiansen 10 Jan, 2023
R.E.D. campaign to solidify IVBH's leadership position within noninvasive early detection after achieving >90% sensitivity in stage I disease detection in expanded data across 5,000+ case-control subjects
By Eric Kristiansen 10 Jan, 2023
Elizabeth Cormier-May, CEO of Mammogen, Inc., and Dragonfly Data Ventures, Partner and CCO of IV BioHoldings, joins SGH Corp. board of directors to provide expertise and strategy to the Company’s medical arm
By Eric Kristiansen 23 Nov, 2022
Experts say lung cancer screening is an important and easy diagnostic test. Weedezign/Getty Images
By Eric Kristiansen 28 Jun, 2022
This multi-year partnership solidifies IV BioHoldings as an AI-powered organization and will further accelerate the company’s clinical and commercial efforts to transform the paradigm of precision health by detecting, diagnosing and treating patients as individuals, at scale.
More Posts
Share by: